Maryam Razavi

maryam.razavi@cambio.se

@CambioCDS

To predict survival in patients with mantle cell lymphoma.

Use in patients presenting with advanced stage mantle cell lymphoma, to help prognosticate and potentially determine therapy. Variables: - Age, years - ECOG: 0-1, 2-4 - Serum LDH, U/L - Upper limit of normal for serum LDH, U/L - WBC *10^9/L - Ki-67 (Optional, for MIPIb) Formula: MIPI = ( 0.03535 × age ) + 0.6978 (if ECOG >1) + [ 1.367 × log10 ( LDH / ULN ) + 0.9393 × log10 ( WBC ) ] If Ki-67 is available: MIPIb = ( 0.03535 × age ) + 0.6978 (if ECOG >1) + [ 1.367 × log10 ( LDH / ULN ) + 0.9393 × log10 ( WBC ) ] + ( 0.02142 x Ki-67 ) Interpretation: MIPI Risk Median overall survival <5.7 Low Not reached (5 year survival 60%) 5.7 to <6.2 Intermediate 51 months ≥6.2 High 29 months MIPIb <5.7 Low Not reached 5.7 to <6.5 Intermediate 58 months ≥6.5 High 37 months

1. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-65. 2. Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014;32(13):1338-46. 3. Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115(8):1530-3.

OBSERVATION.basic_demographic.v1, OBSERVATION.mipi.v0, OBSERVATION.lab_test_ldh.v1, OBSERVATION.lab_test-full_blood_count.v1